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Establishment of an orthotopic
patient‑derived xenograft mouse model using
uveal melanoma hepatic metastasis
Ken Kageyama1,3, Masahiro Ohara1, Kengo Saito1, Shinji Ozaki1,4, Mizue Terai1, Michael J. Mastrangelo1,
Paolo Fortina2, Andrew E. Aplin2 and Takami Sato1*

Abstract
Background: Metastatic uveal melanoma is a highly fatal disease; most patients die from their hepatic metastasis
within 1 year. A major drawback in the development of new treatments for metastatic uveal melanoma is the difficulty in obtaining appropriate cell lines and the lack of appropriate animal models. Patient-derived xenograft (PDX)
tumor models, bearing ectopically implanted tumors at a subcutaneous site, have been developed. However, these
ectopically implanted PDX models have obstacles to translational research, including a low engraftment rate, slow
tumor growth, and biological changes after multiple passages due to the different microenvironment. To overcome
these limitations, we developed a new method to directly transplant biopsy specimens to the liver of immunocompromised mice.
Results: By using two metastatic uveal melanoma cell lines, we demonstrated that the liver provides a more suitable microenvironment for tumor growth compared to subcutaneous sites and that surgical orthotopic implantation (SOI) of tumor pieces allows the creation of a liver tumor in immunocompromised mice. Subsequently, 10 of
12 hepatic metastasis specimens from patients were successfully xenografted into the immunocompromised mice
(83.3% success rate) using SOI, including 8 of 10 needle biopsy specimens (80%). Additionally, four cryopreserved PDX
tumors were re-implanted to new mice and re-establishment of PDX tumors was confirmed in all four mice. The serially passaged xenograft tumors as well as the re-implanted tumors after cryopreservation were similar to the original
patient tumors in histologic, genomic, and proteomic expression profiles. CT imaging was effective for detecting and
monitoring PDX tumors in the liver of living mice. The expression of Ki67 in original patient tumors was a predictive
factor for implanted tumor growth and the success of serial passages in PDX mice.
Conclusions: Surgical orthotopic implantation of hepatic metastasis from uveal melanoma is highly successful in the
establishment of orthotopic PDX models, enhancing their practical utility for research applications. By using CT scan,
tumor growth can be monitored, which is beneficial to evaluate treatment effects in interventional studies.
Keywords: Patient-derived tumor xenograft, Uveal melanoma, Surgical orthotopic implantation, Liver, Mouse
Background
Uveal melanoma, which originates from the iris, ciliary body, or choroid, is highly fatal when it metastasizes. The mortality rate is over 90% within 2 years of
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initial diagnosis of metastasis, and median survival time
ranges from 6 months to 1 year [1, 2]. Approximately
90% of metastatic uveal melanoma deaths are attributed
to hepatic metastasis [2, 3]. Patients who first develop
intra-hepatic metastasis have a shorter survival time than
those who instead first develop extra-hepatic metastasis
[4]. The major drawback in the development of new treatments for metastatic uveal melanoma is difficulty obtaining appropriate cell lines and animal models. In general,
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metastatic UM cell lines are very difficult to establish,
and less than 20 metastatic uveal melanoma cell lines are
currently available in the world. Furthermore, there are
only a limited number of pre-clinical models using metastatic uveal melanoma to test the efficacy of a specific
treatment. Currently available in vivo assays are either a
subcutaneous injection of cell lines derived from uveal
melanoma or retro-orbital injection of liver-selected
murine cutaneous melanoma B16 cells [5, 6]. Given that
uveal melanoma metastases typically colonize the liver
and the genetics of uveal melanoma contrasts with that
of cutaneous melanoma, there is a clear need to develop
more biologically relevant in vivo models to test therapeutic strategies in advanced-stage uveal melanoma.
Patient-derived xenograft (PDX) tumor models, bearing implanted tumors from patients, were developed to
meet the demands of precision medicine. A PDX mouse
model holds promise because it offers a personalized
treatment approach and may be useful to predict clinical prognosis, drug efficacy, and tumor characteristics
[7]. Most PDX models, including previously reported
uveal melanoma PDX models, are made by ectopic subcutaneous implantation due to the ease of this implantation technique [8, 9]. However, subcutaneous PDX
models present fundamental limitations for translational
research due to differences in the anatomic microenvironment from the hepatic site of tumor origin, low
engraftment rate, and slow tumor growth [10–15]. Ideally, patient tumors should be implanted orthotopically
into the same organ from which they were removed
[16]. In the case of metastatic uveal melanoma, this is an
orthotopic liver tumor xenograft model.
Orthotopic liver tumor xenograft mouse models were
first described more than 2 decades ago [17]; however,
these mouse models have not been well utilized due to
technically demanding procedures for the establishment.
The conventional implantation technique [18, 19] is complicated and requires the use of specialized equipment,
including 6-0 to 8-0 fine suture under a microscope.
Tumor and normal liver tissue must be sutured carefully
so that the suture does not injure the fragile liver tissue
and lead to hematoma [20]. To circumvent these technical difficulties, we developed a novel surgical orthotopic
implantation (SOI) technique in which a pocket is made
in the liver parenchyma to houses the tumor entirely
within the parenchyma (liver pocket method), followed
by the closure of incision site with absorbable hemostatic
materials, instead of the suture. Our method provides an
optimal microenvironment for tumor development in the
liver and it is especially suitable for hepatic metastasis
from primary uveal melanoma.
As described above, the main purpose of this study is to
circumvent the limitations of conventional PDX models
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that use subcutaneous implantation by developing an
appropriate orthotopic hepatic PDX model of metastatic
uveal melanoma in the NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ
(NSG) mouse. To develop orthotopic hepatic transplant
models, we first compared the differences in tumor cell
growth in a liver site versus a subcutaneous site using
two metastatic uveal melanoma cell lines, to ascertain
which site provides a more suitable tumor microenvironment for the tumor growth. Then, the feasibility of
SOI of tumor tissues (liver pocket method) was investigated to develop a practical liver tumor xenograft
mouse model for metastatic uveal melanoma. Finally, by
using this method, we attempted to establish orthotopic
PDX mouse models from hepatic metastasis samples
from 12 different uveal melanoma patients. We evaluated concordance for tumor characteristics between
pre-implanted and post-implanted tumors. To our
knowledge, our study is the first demonstration of an
orthotopic hepatic PDX transplant model for metastatic
uveal melanoma.

Results
Liver is a suitable microenvironment to support growth
of metastatic uveal melanoma cell lines

To compare growth characteristics of human uveal melanoma cells at hepatic and subcutaneous xenograft sites in
the mouse, TJU-UM001 and TJU-UM004 single cell suspensions were injected at 1 × 106 cells into the liver and
the subcutaneous site, respectively (Fig. 1). At 8 weeks
after injection, UM001 tumors were confirmed to be
engrafted in the liver in three mice (Table 1). In contrast, the subcutaneous site did not engraft the UM001
tumors, although mice were observed for up to 12 weeks
after injection. UM004 tumors grew at both the liver and
subcutaneous sites; however, UM004 tumors were significantly larger in the liver than the subcutaneous site at
4 weeks after injection. To re-examine whether UM001
cells can grow at the subcutaneous site, three different
cell titers (2, 5, and 10 × 106 cells) of UM001 cells were
injected, but UM001 tumors did not form by 12 weeks
post injection. Only the cicatrix of a tumor was found
at 12 weeks when a higher number of tumor cells was
injected into the subcutaneous site. These findings indicate that compared to the subcutaneous site, the liver
offers a more suitable microenvironment to grow the
metastatic uveal melanoma cell lines.
Surgical orthotopic implantation (SOI) using the liver
pocket method generates a liver tumor xenograft model

To develop a practical liver tumor xenograft model, a
novel procedure for SOI of the tumor piece (liver pocket
method) was developed. Donor tumors, which were generated in mouse host livers by injecting uveal melanoma

Kageyama et al. J Transl Med (2017) 15:145
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Fig. 1 a Schematic overview of liver and subcutaneous tumor implantation by needle injection using established cell lines. For mice injected with
tumor suspensions into the liver, tumor volume was measured at sacrifice. Liver UM001 tumor-bearing mice were sacrificed at 8 weeks and UM004
tumor-bearing mice were sacrificed at 4 weeks post-injection. For mice injected with tumor suspensions at the subcutaneous site, tumor volume
was measured three times (4, 8, and 12 weeks) before the mice were sacrificed at 12 weeks post-injection. b–p Macroscopic, histopathological, and
radiological features of liver and subcutaneous tumors generated with established cell lines. b, j Laparotomy image. c, h, k, p Macroscopic findings
for resected tumors. d, l Cut surface of the tumor. e, m Sagittal imaging using CT, black arrows indicate tumors. f, n H&E staining, ×10, Scale bar
1 mm. g, o Macroscopic findings for subcutaneously injected sites. i H&E staining, ×400, Scale bar 50 µm. SC subcutaneous site
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cell lines, were surgically transplanted into the livers of
recipient mice (Fig. 2). This new SOI with liver pocket
method was successfully performed on all 20 recipient
mice, with ten receiving UM001 tumor pieces and ten
receiving UM004 tumor pieces (Additional file 1: Table
S1). Median operation time was 22 min, and median
blood loss during the operation was 0.13 g. Adverse
events, such as hematoma, bile leakage, and tumor deviation, did not occur in any of the 20 mice. Half of the 20
mice were sacrificed at day 1 post-implantation (5 UM001
mice and 5 UM004 mice). An autopsy confirmed that
tumors remained localized in the parenchyma of the liver
without any tumor deviation in these ten mice (Fig. 2).
The remaining ten mice were sacrificed later (five UM001
mice at 8 weeks post-implantation and five UM004 mice
at 4 weeks post-implantation). For comparison with the
liver implanted tumors, tumor pieces generated from the
uveal melanoma cell lines were also implanted at the same
time into the subcutaneous site in ten additional mice
(five mice for UM001 and five mice for UM004).
As shown in Table 1 and Additional file 2: Figure S1,
all recipient mice in which tumor pieces were directly
transplanted into the liver using the liver pocket method
developed tumors in their liver. By comparison, the mice
in which tumor pieces were implanted subcutaneously
exhibited much smaller tumors at the same respective
time points. Neither of the mouse groups developed
tumors anywhere except at the implanted sites. The ratio
of Ki67-positive cells was higher in the liver tumors than
in the subcutaneous tumors for both cell lines tested
(UM001 recipient liver vs. recipient subcutaneous site,
p < 0.001; UM004 recipient liver vs. recipient subcutaneous site, p < 0.001) (Table 1).
Concordance for tumor characteristics between donor
and recipient tumors in the liver

The expression of three different melanoma markers
(HMB45, MelanA, and S100) and a cell proliferation
marker (Ki67) was similar between donor and recipient
tumors generated from the UM001 and UM004 cell lines
(Additional file 3: Figure S2a). The ratio of Ki67-positive
cells in the liver was transiently decreased at 1 day postimplantation; however, the ratio of Ki67-positive cells
was similar between donor and established recipient liver
tumors (UM001 donor liver vs. recipient liver, p = 0.785;
UM004 donor liver vs. recipient liver, p = 0.786)
(Table 1). By reverse phase protein array (RPPA) analysis, both donor and recipient liver tumors showed highly
matching tumor characteristics with respect to protein expression, yielding Pearson correlation analysis
results of r2 = 0.9559, p < 0.001 for UM001 tumors and
r2 = 0.8741, p < 0.001 for UM004 tumors, respectively
(Additional file 3: Figure S2b, c).
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Establishment of an orthotopic patient‑derived liver
metastatic uveal melanoma xenograft model

After establishing the SOI method in NSG mice, we
investigated whether an orthotopic PDX mouse model
can be established using hepatic metastasis specimens
from actual uveal melanoma patients. Patient-derived
tumor specimens were obtained by core biopsy (n = 10)
or surgery (n = 2) from 12 uveal melanoma patients
with hepatic metastasis. These patient-derived tumor
specimens were implanted to the liver of NSG mice,
and the NSG mice were observed up to six months. All
mice were sacrificed at 6 months post-tumor implantation after contrast-enhanced CT imaging evaluation. As
shown in Table 2; Fig. 3a–h and Additional file 4: Figure
S3, 10 PDXs were established successfully from the 12
patients (engraftment rate 83.3%) within 6 months. Overall, tumors were confirmed in 18 of 27 implanted mice
(66.7%). The presence of tumors was confirmed by contrast enhanced CT imaging in all cases. It is of note that
needle biopsy specimens successfully engrafted in 8 of 10
patients (80%). Since hepatic metastasis tends to develop
in both lobes of the liver, surgical removal of the tumor is
not a feasible option for the majority of patients. In this
regard, the successful PDX tumor establishment from
core biopsy specimens is highly encouraging.
To maintain PDX tumors in NSG mice, tumors
obtained from the first generation of mice (X1) were serially transplanted to the next cohorts of mice (X2 and X3).
All 10 xenograft tumors were successfully transplanted
into second-generation mice (X2). We were able to serially passage 6 of 10 PDX tumors and engraft them into
third-generation mice (X3). By examining the expression
profiles of the original patient tumors, we found that high
expression of Ki67 was a predictive factor for their ability to undergo serial passaging and successful engraftment into the third-generation mice (p < 0.05) (Table 3).
The ratio of Ki67-positive cells in original patient tumors
correlated significantly with median tumor volume in
first-generation mice (Pearson correlation analysis of
r2 = 0.699, p < 0.01; Fig. 3i). Collectively, these results
indicate that high expression of Ki67 in parental tumors
confers enhanced tumor growth and successful serial
passages in PDX mice.
Reimplantation of cryopreserved tumors

After successful engraftment of patient-derived xenograft
tumors in first-generation mice (X1), three 1-mm cubes of
chunks from individual PDX tumors obtained from cases
2, 5, 7, and 12 were cryopreserved in liquid nitrogen using
three different cryopreservation media (F, D, R medium
respectively). After cryopreservation, these cryopreserved
PDX tumor specimens were re-implanted. All cryopreserved PDX tumor chunks except one in F medium

Kageyama et al. J Transl Med (2017) 15:145
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Fig. 2 a Schematic overview of the surgical implantation of tumor pieces into the liver and a subcutaneous site. Tumor mass was generated in
donor mice following injection of UM001 and UM004 cell lines to the liver, as described in Fig. 1a. Tumor mass was harvested from the donor mouse
and cut into 1 mm cubes. These small tumor pieces were transplanted into the liver or a subcutaneous site of recipient mice. UM001- and UM004derived tumor pieces were separately implanted into the liver in 10 mice for each cell line. Five mice were sacrificed at 1 day after implantation. The
remaining five mice were sacrificed at 8 weeks after implantation for UM001, or 4 weeks after implantation for UM004, respectively. Furthermore,
UM001- and UM004-derived tumor pieces were also separately implanted into the subcutaneous site in five mice for each cell line. The five mice
were sacrificed at the same time points as the liver tumor-bearing mice. b–i Histopathological features of implanted tumors in the liver at 1 day
post implantation using established cell lines. b, f Laparotomy image. c, g Macroscopic findings for resected tumor. d, h Cut surface of the tumor. e,
i H&E staining, ×40, Scale bar 500 µm

from case 7 were successfully engrafted into the livers of
recipient mice, as were freshly transplanted tumor pieces
without cryopreservation (Table 4). Tumor volumes of

the cryopreserved tumors were smaller than those of the
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6 months after tumor transplantation. Among the three
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Fig. 3 a–h Two representative examples of the histopathological and radiological features of the uveal melanoma PDX models. a, c Laparotomy. b,
d Macroscopic findings for resected liver, showing left lobe with tumor. e, g Axial imaging on CT. f, h Sagittal imaging on CT. Black arrows indicate
patient-derived xenograft tumors. i Correlation between the ratio of Ki67-positive cells in original patient tumors and median tumor volume in firstgeneration mice bearing the corresponding patient-derived tumors. y = 0.1054x + 0.725, r = 0.836, r 2 = 0.699, p < 0.01. Linear scale is converted to
logarithmic scale for tumor volume

freezing methods tested, Cryomedium D (DMEM containing medium) resulted in the highest growth rates following thawing and re-implantation of the frozen tumor
samples. Despite the slower growth of the cryopreserved
tumor specimens, the ratio of Ki67-positive cells in the
cryopreserved tumors was similar to that of the directly
transplanted tumors. From these studies, we conclude that

while cryopreserved tumors can be successfully engrafted
in mice, the growth of cryopreserved tumor samples is
reduced compared to the directly transplanted, non-frozen
tumor samples. Considering comparative Ki67 activity in
established PDX tumor specimens in X2 mice, this is most
likely due to loss of a fraction of proliferative tumor cells in
the cryopreserved tumor chunks.
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Table 3 Predictive factors for successful engraftment of PDX tumor
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of 1st-generation mice ( X1)

p value Achievement
of serial passages to 3rdgeneration mice
(X3)

Success Failure
Patient gender

n = 12

Male

5

1

Female

5

1

Age
≥60

<60

Tumor sample

n = 12

4

2

6

0

n = 12

Surgery

2

0

Biopsy

8

2

Pigmentation

n = 12

None

4

1

Pigments

6

1

Ki67 (%)
≥10

<10

Monosomy 3

n = 11

6

0

4

1

n = 10

Positive

7

1

Negative

1

1

p value

Engraftment
of 1st-generation mice (X1)

Success Failure

1.00

0.454

1.00

1.00

0.455

0.378

n = 12

3

3

3

3

n = 12

4

4

2

n = 12

1

5

5
2

3

4

High gain 6

1

Low gain

1

0.567

1.00

1.00

0

0

5

0.002

2

0

2

0.133

n = 10

4

0

Negative

5

1

n = 10

Positive

3

0

Negative

6

1

n = 10

Positive

5

0

Negative

4

1

n = 10

Positive

1

1

Negative

8

0

EIF1AX

6

2

Positive

SF3B1

6

n = 10

c-myc gain n = 10

BAP1

3

n = 11

1.00

GNA11

1

n = 12

Success Failure

GNAQ

2

p value Achievement
of serial passages to 3rdgeneration mice
(X3)

n = 10

Positive

0

0

Negative

9

1

p value

Success Failure

1.00

1.00

1.00

1.00

0.200

1.00

n = 10

5

2

1

2

n = 10

3

1

3

3

n = 10

2

1

4

3

n = 10

4

1

2

3

n = 10

0

2

6

2

n = 10

0

0

6

4

0.500

0.571

1.00

0.528

0.133

1.00

Large 4 copies, Small 3 copies or partial 4 copies

Xenograft tumors histologically resemble the original
hepatic metastasis obtained from patients

Hematoxylin and eosin (H&E) staining revealed a strong
concordance between the histopathological features of
the patient tumors and their corresponding xenograft
tumors in mice (Fig. 4a and Additional file 5: Figure S4).
Xenograft tumors retained a similar degree of pigmentation as observed in the original patient tumors (Table 2).
Serially passaged xenograft tumors also retained the
same morphology and pigmentation as their original
patient tumors. The three melanoma markers (HMB-45,
Melan-A, and S100) were expressed at similar relative
levels in patient tumors and their corresponding xenograft tumors. Furthermore, the ratio of Ki67-positive
cells in the original tumors was also akin to that in the
corresponding xenograft tumors.
Xenograft tumors retain mutations present in their
parental patient tumors

We identified five representative mutations in uveal melanoma. In 10 out of 12 samples available for mutation
analysis, the xenograft tumors contained the exact same
mutations as their corresponding original patient tumors.
An exception was observed for case 11 at the EIF1AX
locus (Table 2). The mutation rate for five representative

mutations was 40, 30, 50, 20, and 10% in GNAQ, GNA11,
BAP1, SF3B1, and EIF1AX, respectively. Mutations in
GNAQ and GNA11 were mutually exclusive, as were
mutations in BAP1, SF3B1, and EIF1AX with each other.
For PDX cases 2, 5 and 12, a total of nine tumor samples
re-implanted after cryopreservation also retained the
same mutational profiles as their corresponding original
patient tumors.
Xenograft tumors preserve the DNA copy number
alterations in their original patient tumors

The patterns of copy number variations (CNVs) in the
original patient tumors are mostly maintained in the corresponding first-, second-, and third-generation xenograft
tumors, as well as in tumors generated by re-implantation
of cryopreserved samples (Fig. 4b; Additional file 6: Figure S5). CNVs in tumors displayed representative characteristics of uveal melanoma cells, including monosomy 3
accompanied by chromosome 1p loss, 8q gain, and 8p loss.
In particular, the 8q gain was observed in all 12 cases, as
was c-myc amplification in 8q. For cases 8 and 11, CNVs
in patient tumors did not match the corresponding original
tumors. These patient tumors showed a normal pattern of
CNVs because of the very small volumes of tumor in the
biopsy specimen, whereas the xenograft tumors displayed
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Table 4 Results for re-implantation of cryopreserved tumors
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Fig. 4 a Two representative examples of histopathological features of patient tumors and the corresponding xenograft tumors. H&E-stained sections and immunostained sections with HMB-45, Melan A, and S-100 antibodies, ×400. Scale bar 50 µm. Patient tumors are depicted in the columns
1 and 4. The corresponding xenograft tumors are depicted in columns 2 and 3, and 5 and 6, respectively. Control panels show no positive signal with
an isotype control antibody (inset images located at bottom right in each immunostaining panel). X0 Patient original tumors, X1 PDX tumors in the
first-generation mice, X2 PDX tumors in the second-generation mice. b Two representative examples of DNA copy number variation with karyogram. Individual chromosomes are shown in the karyograms, with bars on the right side of the karyograms indicating the chromosomal locations
of copy number losses and gains, respectively. Chromosomes 1 to 12 are lined up on the top and chromosome 13 to 22, X and Y are on the bottom.
From left to right, patient tumor ( X0) is at the left with its adjacent karyogram, the corresponding first-generation xenograft tumor ( X1) is in the second column, the corresponding second-generation xenograft (X2) is in the third column, and three different xenograft tumors generated from frozen
tumor specimens using F, D and R cryopreservation medium are in the fourth to sixth columns. A copy number of 2 (normal) is indicated by blank
space (no color); copy number greater than 2 (chromosomal gain or amplification) is indicated in blue; and copy number less than 2 (chromosomal
loss or deletion) is indicated in red
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a typical pattern of uveal melanoma CNVs. Unsupervised
hierarchical clustering using patterns of CNV revealed that
patient tumors clustered with the corresponding xenograft
tumors and the corresponding cryopreserved tumors in 10
successful engraftment cases (Fig. 5a).
Stability of xenograft tumors on their proteome
as determined by reverse phase protein array (RPPA)

We performed RPPA on nine paired original patient
tumors and the corresponding xenograft tumors for ten
successful engraftment cases (excluding case 11 due to
unavailability of tumor samples). The related samples
clustered together regarding their protein expression
profiling, thus demonstrating stability at the level of the
proteome between the original patient tumors and their
subsequently derived PDX tumors (Fig. 5b).

Discussion
To generate PDX mouse models, the ectopic subcutaneous implantation method has been used due to quick
implantation of tumors and ease of monitoring [8].
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However, orthotopic engraftment of the tumor is more
rational for a PDX model because tumor cells reside in
the similar microenvironment as the original tumor [21,
22]. For example, orthotopic soft-tissue sarcoma xenografts retained the same morphology as primary tumors,
whereas ectopically implanted xenograft tumors altered
their morphology due to the influence of the tumor
microenvironment [23]. Orthotopic breast tumor xenografts were considered to be more accurate models for
tumor microenvironment and clinical cancer progression compared with the subcutaneous xenografts [24].
Similarly, lung and colon cancer xenograft mouse models
respond differently to chemotherapy, depending on the
sites of transplantation [25, 26]. Collectively, these studies indicate that patient-derived orthotopic xenograft
(PDOX) tumor models mirror the corresponding patient
tumors more accurately than models using ectopic
implantation sites [16].
Our liver pocket method makes surgical orthotopic
implantation (SOI) in the liver simpler than the conventional techniques, allowing us to finish implantation of

Fig. 5 a Unsupervised hierarchical clustering of paired patient tumors and xenograft tumors based on DNA copy number analysis. X0 Patient original tumors, X1 PDX tumors in the first-generation mice, X2 PDX tumors in the second-generation mice, F F medium (90% fetal bovine serum/10%
DMSO), D D medium (70% DMEM/20% fetal bovine serum/10% DMSO); R R medium (70% RPMI/20% fetal bovine serum/10% DMSO). b Unsupervised hierarchical clustering of paired patient tumors and xenograft tumors based on reverse phase protein array (RPPA) analysis

Kageyama et al. J Transl Med (2017) 15:145

patient tumor tissues into the liver in less than 5 min,
most of which time is required for closing the abdomen with a double-layer suture. Absorbable hemostatic material plays a major role in sealing the incision
and preventing bleeding. Average bleeding volume was
approximately less than 10% of circulating blood volume
in mice [27]. Because the hemostatic materials prevented
surgical bleeding, we were able to operate with greater
confidence and achieve excellent survival outcomes for
our PDX mouse models without treatment-related death.
Although PDX models have proven to be useful for
cancer research, there are still some obstacles to their
use in translational research [7, 28, 29]. First, engraftment failure occurs at a high rate for some tumors,
including subcutaneous implantation of uveal melanoma
[9, 13, 14]. It is essential to improve tumor engraftment
so that a larger number of PDX models can be successfully generated, enabling them to be effectively utilized
for tumor data profiling and mouse drug efficacy trials,
and avoiding selection bias of PDX models due to poor
engraftment rate. In our study, we found that the orthotopic hepatic implantation technique enhanced the rate
of tumor engraftment of metastatic uveal melanoma,
compared to subcutaneous implantation with uveal melanoma metastases [9]. Additionally, most PDX studies
have required surgically harvested tumor materials, not
needle biopsy specimens [7] to obtain sufficient amounts
of tumor specimens from patients. Engraftment failure is
commonly encountered in core biopsy samples containing fewer tumor cells. In this regard, the high success rate
of engraftment in our method is encouraging and suggests that core biopsy specimens can be used effectively
to generate PDX models by orthotopic implantation.
One of the disadvantages of PDX models for drug
screening is the discrepancy between engraftment time
in mice and imminent treatment schedules for patients,
which limits timely personalized pre-clinical drug trials using PDX models [7, 28]. Our study harvested the
tumors in less than 6 months post-implantation, which is
shorter than the time required for tumor establishment in
subcutaneous implantation models; however, additional
time is still needed to generate second- or third-generation PDX mouse models for personalized drug trials. We
plan to investigate whether we can develop PDX tumors
from primary uveal melanoma. If this approach is successful, we might be able to develop PDX tumor models
from individual patients before these patients develop
actual systemic recurrence, which would help patients
select the most appropriate course of treatment.
It has been reported that serial transplantation of tumors
to recipient mice causes genetic drift [30, 31]. In general,
multiple passages of PDX models or changing the site of
implantation are not recommended to preserve the genetic
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and proteomic consistency of the original patient tumor.
Serial passages might cause genomic rearrangements
intrinsic to tumor adaptation [28]. This is a serious concern to use uveal melanoma cell lines established from PDX
tumors for the purpose of pre-clinical drug screening to
design early phase clinical trials. To minimize genetic and
proteomic alterations, we orthotopically implanted liver
tumors into the equivalent organ in mice. In 10 successful cases, both the original tumors and the corresponding
xenograft tumors show the same tissue histologic features
in H&E staining and immunohistochemistry, mutations
and CNV in genomic analyses, and RPPA in proteomic
analyses. Therefore, SOI with hepatic metastasis is a reliable method to create PDX mouse models that retain the
characteristics of original patient tumors. Furthermore, it
is preferable to restrict PDX models to a low passage number to maintain tumor characteristics of the original tumor
[31]. In this regard, biobanking of PDX tumors will be critical to store patient tumors and their corresponding xenograft tumors for re-implantation when required [32]. Our
preliminary studies indicate that re-implantation of cryopreserved tumors is feasible without changing the characteristics of PDX tumors. This cryopreservation approach
will facilitate the expansion of our PDX platform for largescale pre-clinical drug screening using PDX tumors.
Cytogenetic investigations have revealed that most
uveal melanomas have abnormal chromosomes 1, 3, 6
and 8 [33, 34]. Monosomy 3 is observed in 50% of uveal
melanoma, and 70% of patients with monosomy 3 die of
metastases within four years after the initial diagnosis,
whereas patients with disomy 3 (normal chromosome 3)
rarely develop metastatic uveal melanoma [35]. Recently,
researchers have identified mutations in BAP1 gene,
located on chromosome 3, and this gene seems to play a
major role in tumor progression in uveal melanoma [36].
Also, a gene expression profiling (GEP) assay demonstrated that class 2 is the most accurate poor prognostic
marker for patients with uveal melanoma [37, 38]. A previous PDX study reported that tumors from patients having monosomy 3 or class 2 in GEP were relatively easy to
engraft into mice [39]. However, in our study, monosomy
3 and BAP1 mutations did not clearly correlate with the
success rates of engraftment and serial passage. On the
other hand, high expression of Ki67 contributed to the
success of serial passages. Ki67 positivity is reported to
be strongly associated with class 2 in GEP and monosomy 3 [40]. The expression of Ki67 was marginally correlated with monosomy 3 in our study (data not shown,
p = 0.0556). Ki67 has an important role in cell proliferation and tumor progression in uveal melanoma. The relative expression level of Ki67 might, therefore, be a useful
parameter for predicting the establishment of a given
uveal melanoma tumor in our PDX platform.
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A major drawback of orthotopic hepatic PDX models is
difficulty in measuring tumor growth. In this regard, we
confirmed that CT scan is exceedingly helpful in evaluating tumor growth in the liver. The use of commercially
available CT contrast agent allows detection and visualization of interior liver tumors in live animals. The contrast agent specifically enhances normal mouse liver
parenchyma on the CT so that it is easy to recognize the
unenhanced site as the tumor [41]. It also detects small
tumors less than 1 mm, which arise as daughter nodules
around the main tumors. This imaging approach will be
highly beneficial for testing new agents for cancer treatment by accurately measuring tumor size, which is essential in human clinical trials.
Our model has some limitations that we expect to
address in future work. First, xenograft tumors are surrounded by mouse tissue, even though they are orthotopically implanted. Patient-derived xenograft tumors are
thus destined to be fostered by mouse vessels and tissues.
Liver metastasis mouse models using human uveal melanoma cell lines contain mouse-derived vessels within
the tumor [42]. Since growth factors, cytokines, and
chemokines could have species-specificity, PDX mouse
models might not be the best model to investigate interactions between the tumor and its microenvironment. In
this regard, a chimeric mouse model with a humanized
liver would provide a better human tissue microenvironment for the implanted human tumors to the liver [43].
Another major challenge to the PDX approach is the lack
of tumor-immune system interactions. A humanized
immune system mouse, such as a hu-BLT and hu-PBMC
mouse, might be preferable for some aspects of future
PDX research [44, 45].

Conclusions
In conclusion, orthotopic PDX models can be developed
from hepatic metastases of uveal melanoma patients with
the liver pocket method. With CT scan imaging technology, development and growth of hepatic tumors in
NSG mice can be easily monitored. This is considered
to be much more close to the clinical situation of actual
patients, compared to ectopic transplantation of tumor
specimens to subcutaneous site devoid of liver microenvironment. Pre-clinical investigation of specific signal
blockades using this orthotopic PDX model should be
warranted.
Methods
Regulatory and ethical considerations

Patients provided written consent allowing the use of
tissue samples for this research, according to an Institutional Review Board-approved protocol. The animal study
was approved by the Institutional Animal Care and Use

Page 14 of 19

Committee of Thomas Jefferson University and adhered to
the recommendations in the National Institutes of Health
Guide for the Care and Use of Laboratory Animals.
Metastatic uveal melanoma cell lines

TJU-UM001 and TJU-UM004 cell lines were established
in our laboratory at Thomas Jefferson University and
authenticated by the DDC Medical (Fairfield, OH, USA).
They are derived from a liver metastasis and an orbital
metastasis of human uveal melanoma, respectively. Both
UM001 and UM004 cells harbor the Q209L mutation as
determined by Sanger DNA sequencing, as previously
described [46, 47]. UM001 cells were cultured in RPMI
1640 medium supplemented with 10% heat-inactivated
FBS, 10% non-essential amino acids, 2 mM l-glutamine,
10 mM HEPES buffer, 50 IU/ml penicillin and 50 mg/
ml streptomycin. UM004 cells were cultured in MEM
medium containing 10% heat-inactivated FBS, 50 IU/ml
penicillin and 50 mg/ml streptomycin.
Patient‑derived liver metastatic uveal melanoma samples

Tumor specimens were obtained after surgery or biopsy
from liver metastatic uveal melanoma patients. Tumor
masses were washed with sterile PBS and were cut
into 1 mm cubes for implantation into the mouse liver
(Fig. 6a). Procurement of tumor specimens and tumor
implantation were performed within 2 h.
Animals

Eight-week-old male and female NSG mice (Jackson
Laboratory, Bar Harbor, ME, USA) were used for tumor
injection or implantation into the liver or a subcutaneous
site. For the tumor injection or implantation, each mouse
was anesthetized with 3% Isoflurane for induction and
2% for maintenance.
Laparotomy

Mice were placed on a heating pad in the supine position.
A 1 cm skin incision was made in the left subcostal area,
followed by a 1 cm incision in the peritoneum to expose
the liver. Using a cotton swab, the left lobe of the liver
was moved outside the body and placed on a nonwoven
absorbent fabric sheet for the injection or implantation.
After the injection or surgical implantation, the liver was
returned within the body, and the abdominal incision
was closed in 2 layers with 5-0 polydioxanone absorbable
thread (AD Surgical, Sunnyvale, CA, USA).
Needle tumor injection into the liver and subcutaneous
site

UM001 cells (1 × 106) in 20 μl of RPMI 1640 or UM004
cells (1 × 106) in 20 μl of MEM were mixed with Matrigel
(BD Biosciences, Bedford, MA, USA) (mixing ratio of
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Fig. 6 Surgical orthotopic implantation using the liver pocket method. a Small tumor pieces to be implanted. b Liver is exposed. c Liver is moved
outside the abdominal cavity. d Liver pocket is produced by surgical incision. e Tumor piece is inserted into the liver. f Incision is covered and bleeding is halted using hemostatic materials. g Liver is returned into the abdominal cavity

2:1) and injected directly under the surface of the left
lobe of the liver with a Hamilton syringe using a 27 G
needle (Hamilton Company, Reno, NV, USA) [42]. For
subcutaneous injection, UM001 cells or UM004 cells
(1.0–10.0 × 106) were injected with a 25 g needle into a
subcutaneous site in the hind limb. The subcutaneously
injected tumors were measured up to 12 weeks by caliper.
Surgical orthotopic implantation using liver pocket
method

The left lobe of the mouse liver was exposed by laparotomy (Fig. 6b, c). The liver was incised using a No. 11 sharp
scalpel (AD Surgical, Sunnyvale, CA, USA) horizontally
in parallel with the surface of the liver to form a pocket
in the parenchyma without cutting any major vessels
(Fig. 6d). A tumor piece was implanted into the pocket
(Fig. 6e). The incision site was then sealed with absorbable
hemostatic material (SURGICEL, Johnson and Johnson,
New Brunswick, NJ, USA) to curtail bleeding (Fig. 6f )
[48]. The liver was returned to its original position after
confirming hemostasis from the liver (Fig. 6g).
Surgical implantation at subcutaneous sites

A 3-mm incision was made in the skin of the hind limb.
Scissors were inserted into the subcutaneous space to
create a pocket. A tumor piece was inserted into this subcutaneous pocket, and then the incision was closed with
5-0 polydioxanone absorbable thread.

CT imaging and contrast agent

Micro-CT scan (Inveon Micro-CT, Siemens, Germany)
was performed 4 h after injection of contrast agent. The
contrast agent (ExiTron nano 12000, Miltenyi Biotec,
Germany) is an alkaline earth-based nanoparticulate
contrast agent for mouse liver CT imaging [41]. Upon
intravenous injection, the agent is taken up by cells of
the reticuloendothelial system, including macrophages
within the liver, termed Kupffer cells. Mice were injected
with 100 µl of agent (per mouse, 25–30 g body weight)
via a lateral tail vein.
Collection of tumor masses from mice

UM001 tumors, UM004 tumors, or patient-derived
xenograft tumor masses were collected from the mice
at the scheduled time of sacrifice. The tumor volume was  calculated
 using the following formula:
Volume = W2 × L /2, with W being the shortest diameter and L being the longest diameter. Resected tumors
were washed with sterile PBS. A portion of the tumor
was cut into 1 mm cubes for implantation into the liver of
recipient mice. The remaining tumor was used for analyses of tumor characteristics and cryopreservation.
Cryopreservation and thawing procedure

Tumor masses from established PDX mouse models
were cut into 2 mm cubes and transferred to sterile cryotubes containing one of 3 different cryomedia: F medium
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(90% fetal bovine serum/10% DMSO), D medium (70%
DMEM/20% fetal bovine serum/10% DMSO), and
R medium (70% RPMI/20% fetal bovine serum/10%
DMSO). Cryotubes were placed in a freezing chamber
containing isopropanol within a −80 °C freezer, which
froze the samples at a rate of −1 °C/min. Frozen tumor
specimens were transferred to liquid nitrogen storage
the next day. For thawing, cryotubes were incubated in
a water bath (37 °C) until melted. Thawed tumors were
washed with sterile PBS and then cut into 1 mm cubes
for implantation into the liver of recipient mice.
Histology and immunohistochemistry

For histopathological evaluation, H&E staining was performed on paraffin-embedded tumor tissue sections. The
degree of pigmentation of tissue samples was assessed based
on the Collaborative Ocular Melanoma Study (COMS) classification system [49]. For immunohistochemistry, sections
were stained with primary antibodies overnight at 4 °C. On
the next day; sections were incubated for 30 min in ImmPRESS AP Reagent (Vector Laboratories, Burlingame, CA,
USA), followed by incubating for 2–15 min in ImmPACT
NOVA-RED (Vector Laboratories). The following primary
antibodies were purchased from Agilent (Santa Clara, CA,
USA): Melanosome (Clone HMB45), Melan-A, S100, and
Ki67. All sources of specific antibodies for these markers
and their dilution rates have been previously described [42]
except for Ki67 (dilution rate; 1:50). Staining data for Ki67
were quantitated by counting all positive nuclei per field of
vision at ×400 magnification using ImageJ software (available at http://rsb.info.nih.gov/ij) [40].
Reverse phase protein arrays (RPPA)

Harvested tumor tissues were lysed and processed
according to the MD Anderson RPPA Core Facility
protocol (available at https://www.mdanderson.org/
education-and-research/resources-for-professionals/
scientific-resources/core-facilities-and-services/index.
html). Protein was isolated from tumor chunks, adjusted
to 1 to 1.5 mg/ml, boiled for 5 min after the addition of
4× SDS sample buffer, stored at −80 °C, and submitted
to the MD Anderson RPPA Core Facility. Lysates were
tested using a panel of 299 validated antibodies, and analyses were performed on normalized data. Unsupervised
hierarchical cluster analysis based on Pearson distance
combined with average linkage was performed using
MeV 4.8 (Multiple Experiment Viewer) (Dana-Farber
Cancer Institute, Boston, MA, USA) [50].
Genomic studies detecting mutations and DNA copy
number variants

DNA was extracted from the tumor samples with QIAmp
DNA Mini Kit (Qiagen, Valencia, CA). Genomic libraries
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were prepared using extracted DNA and customized
for the Truseq Amplicon Cancer Panel Kit (Illumina,
San Diego, CA, USA). The mutational status of GNAQ,
GNA11, BAP1, SF3B1, and E1F1AX genes was assessed
using the Miseq sequencer (Illumina) [51]. Specific mutations and primers for all of these genes are detailed in
Additional file 7: Table S2. Genomic DNA samples were
analyzed for reproducibility of genome-wide copy number, loss of heterozygosity, and somatic mutations using
a single nucleotide polymorphism (SNP) microarray
provided by the Affymetrix CytoScan HD Array platform (Affymetrix, Santa Clara, CA). Data analysis was
performed using the Chromosome Analysis Suite software package (Affymetrix). Copy number gains and
losses >1 MB are reported in this analysis. Genomic
studies were performed at Cancer Genome Core Facility of Sideny Kimmel Cancer Center at Thomas Jefferson
University (Director, Dr. Paolo Fortina). Unsupervised
hierarchical cluster analysis based on Euclidean distance
combined with complete linkage was performed using
the hclust function in R version 3.3.0 (available at http://
www.r-project.org).
Statistical analysis

Data with non-normal distributions are presented with
median and range. The non-parametric Mann–Whitney
U-test was performed for comparison of Ki67 expression
levels. The Pearson correlation test was performed to
assess consistency of two samples in RPPA analysis and
to examine correlations between Ki67 expression and
tumor volume. A regression line between two samples
was generated, and the correlation coefficient (r) was calculated. Fisher’s exact test was performed to identify predictive factors for the success of engraftment and serial
passages. Groups were considered to be significantly
different at p < 0.05. Statistical analyses were performed
by GraphPad Prism (GraphPad Software, La Jolla, CA,
USA).

Additional files
Additional file 1: Table S1. Results of orthotopic tumor implantation to
the liver using hepatic tumor specimens derived from metastatic uveal
melanoma cell lines.
Additional file 2: Figure S1. a–p: Macroscopic, histopathological,
and radiological features of liver-implanted tumors and subcutaneously implanted tumors using metastatic uveal melanoma cell lines. a, i:
Laparotomy image. b, g, j, o: Macroscopic findings for resected tumors. c,
k: Cut surface of the tumor. d, l: Sagittal imaging on CT, Black arrows indicate tumors. e, m: H&E staining, x10, Scale bar, 1 mm. f, n: Macroscopic
findings for subcutaneously implanted sites. h, p: H&E staining, x40, Scale
bar 500 µm. Abbreviation: SC = subcutaneous site.

Additional file 3: Figure S2. a: Representative biomarker expression patterns in donor and recipient tumors. Immunostaining with four
antibodies as indicated. Donor sections are depicted in the columns 1 and
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3; recipient sections are depicted in the columns 2 and 4. Control panels
exhibit no signal with isotype control antibody, as shown by the inset
images at bottom right in each immunostaining panel, x400. Scale bar 50
µm. b and c: RPPA correlation between donor tumors and tumors developed in the recipient mice using UM001 and UM004 cells. The scatterplot
with a linear regression line shows a linear association between the donor
tumors and the recipient tumors. b: y = 1.002 x + 0.018, r = 0.9560, r 2 =
0.914, p < 0.001. c: y = 1.085 x + 0.026, r = 0.9349, r 2 = 0.874, p < 0.001.
Additional file 4: Figure S3. Macroscopic and radiological features of
eight PDX models. Left panels: Laparotomy. Right panels: Axial images
of CT scan. Black arrows denote patient-derived xenograft tumors.

Additional file 5: Figure S4. Histopathological features of patient
tumors and corresponding xenograft tumors in three different PDX
models. H&E-stained sections and immunostained sections with HMB-45,
Melan A, and S-100 antibodies, x400. Scale bar 50 µm. Control panels
show no immunostaining with an isotype control antibody (inset image
at bottom right in each stained panel). Abbreviations: X0 = Patient original
tumors ; X1 = PDX tumors in the first-generation mice; X
 2 = PDX tumors in
the second-generation mice; F = F medium (90% fetal bovine serum/10%
DMSO); D = D medium (70% DMEM/20% fetal bovine serum/10% DMSO);
R = R medium (70% RPMI/20% fetal bovine serum/10% DMSO).
Additional file 6: Figure S5. DNA copy number variation with karyogram. Individual chromosomes are shown in the karyograms, with bars
on the right side of the karyograms indicating the chromosomal locations
of copy number losses and gains, respectively. Chromosomes 1 to 12 are
lined up on the top and chromosome 13 to 22, X and Y are on the bottom. Patient tumor ( X0) is at the left with its adjacent karyogram, the corresponding first-generation xenograft tumor (X1) is in the second column,
the corresponding second-generation xenograft ( X2) is in the third column, and three different xenograft tumors generated from frozen tumor
specimens using F, D and R cryopreservation medium are in the fourth to
sixth columns. A copy number of 2 (normal) is indicated by blank space
(no color); copy number greater than 2 (chromosomal gain or amplification) is indicated in blue; and copy number less than 2 (chromosomal loss
or deletion) is indicated in red.
Additional file 7: Table S2. Primers used for amplification and sequencing of genomic DNA.
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